Is Poorly Assisted Psilocybin Treatment an Increasing Risk?
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2024/01/01
-
Journal
-
Indian UGC (journal)
-
Refrences12
-
Citations6
-
Eduardo Ekman Schenberg Instituto Phaneros, São Paulo, Brazil (Schenberg); Massachusetts General Hospital and Harvard Medical School, Boston (King); Psychotherapist in private practice, Lisbon (Fonseca); Department of Psychology, University of Exeter, Exter, United Kingdom; Centre for Psychedelic Research, Imperial College London, London (Roseman).
-
Franklin King Instituto Phaneros, São Paulo, Brazil (Schenberg); Massachusetts General Hospital and Harvard Medical School, Boston (King); Psychotherapist in private practice, Lisbon (Fonseca); Department of Psychology, University of Exeter, Exter, United Kingdom; Centre for Psychedelic Research, Imperial College London, London (Roseman).
-
João Eusébio da Fonseca Instituto Phaneros, São Paulo, Brazil (Schenberg); Massachusetts General Hospital and Harvard Medical School, Boston (King); Psychotherapist in private practice, Lisbon (Fonseca); Department of Psychology, University of Exeter, Exter, United Kingdom; Centre for Psychedelic Research, Imperial College London, London (Roseman).
-
Leor Roseman Instituto Phaneros, São Paulo, Brazil (Schenberg); Massachusetts General Hospital and Harvard Medical School, Boston (King); Psychotherapist in private practice, Lisbon (Fonseca); Department of Psychology, University of Exeter, Exter, United Kingdom; Centre for Psychedelic Research, Imperial College London, London (Roseman).
Cite
Schenberg, Eduardo Ekman, et al. “Is Poorly Assisted Psilocybin Treatment an Increasing Risk?”. American Journal of Psychiatry, vol. 181, no. 1, 2024, pp. 75-76, https://doi.org/10.1176/appi.ajp.20230664.
Schenberg, E. E., King, F., da Fonseca, J. E., & Roseman, L. (2024). Is Poorly Assisted Psilocybin Treatment an Increasing Risk?. American Journal of Psychiatry, 181(1), 75-76. https://doi.org/10.1176/appi.ajp.20230664
Schenberg, Eduardo Ekman, Franklin King, João Eusébio da Fonseca, and Leor Roseman. “Is Poorly Assisted Psilocybin Treatment an Increasing Risk?”. American Journal of Psychiatry 181, no. 1 (2024): 75-76. https://doi.org/10.1176/appi.ajp.20230664.
Schenberg EE, King F, da Fonseca JE, Roseman L. Is Poorly Assisted Psilocybin Treatment an Increasing Risk?. American Journal of Psychiatry. 2024;181(1):75-6.
Journal Categories
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Neurology
Diseases of the nervous system
Psychiatry
You May Also Like
- Short screening scales to monitor population prevalences and trends in non-specific psychological distress
- Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment
- The Eating Attitudes Test: psychometric features and clinical correlates
- Schizophrenia: A Review of Genetic Studies
- Immigration and Mental Health: Mexican Americans in the United States
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Title | 2024 | |||
| Title | 2022 | |||
| Ethical Concerns about Psilocybin Intellectual Property | ACS Pharmacology & Translational Science |
| 27 | 2021 |
| 10.31234/osf.io/u6v9y | ||||
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research | Frontiers in Psychiatry |
| 37 | 2021 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? | European Archives of Psychiatry and Clinical Neuroscience |
| 4 | 2024 |
| Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects | Neuroscience Applied | 2024 | ||
| Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary | American Journal of Psychiatry |
| 3 | 2024 |
| Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary | American Journal of Psychiatry |
| 3 | 2024 |
| Improving Clinical Outcomes and Informing New Interventions | American Journal of Psychiatry |
| 2024 |
Citations Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system: Psychiatry 5
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? and was published in 2024. The most recent citation comes from a 2024 study titled Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?. This article reached its peak citation in 2024, with 6 citations. It has been cited in 3 different journals. Among related journals, the American Journal of Psychiatry cited this research the most, with 4 citations. The chart below illustrates the annual citation trends for this article.